Results 241 to 250 of about 12,744 (284)

Drug Utilization of Intrinsa® (Testosterone Patch) in England

Drug Safety, 2010
Intrinsa is a transdermal testosterone patch that is indicated for use in hypoactive sexual desire disorder (HSDD) in women who have undergone bilateral oophorectomy and hysterectomy (surgically-induced menopause) receiving concomitant oestrogen therapy.To describe the utilization characteristics of the patients prescribed testosterone patch (Intrinsa)
Osborne, Vicki, Hazell, Lorna, Layton, Deborah, Shakir, Saad A.W.   +3 more
openaire   +3 more sources

By pill or by patch, testosterone gets in on the act

Inpharma Weekly, 1999
Various formulations of testosterone have yielded promising results in 3 recent clinical trials involving both women and men. In the first trial, transdermal testosterone improved sexual function and psychological well-being in women with sexual dysfunction after surgically-induced menopause.
openaire   +1 more source

Testosterone-Patch-Induced Psychotic Mania

American Journal of Psychiatry, 1999
E L, Weiss, M B, Bowers, C M, Mazure
openaire   +2 more sources

Two Sustained Release Membranes Used in Formulating Low Strength Testosterone Reservoir Transdermal Patches

Current Drug Delivery
Introduction: Several Testosterone Replacement Therapies exist for hypogonadism, but an in-depth analysis of these products reveals a high dosing frequency and a high drug loading, up to 120 mg for a potent drug like Testosterone. This may lead to patient non-compliance and toxicity problems if used improperly.
Ria Vashishth, Monica C. Chuong, Juan Chang Duarte, Yadnya Gharat, Stephen G. Kerr   +4 more
openaire   +2 more sources

Testosterone patch increases sexual activity in women with hypoactive sexual desire disorder

Nature Clinical Practice Endocrinology & Metabolism, 2005
Testosterone patch increases sexual activity in women with hypoactive sexual desire ...
openaire   +1 more source

Contact allergy to a testosterone patch

Contact Dermatitis, 1998
D A, Buckley, S M, Wilkinson, E M, Higgins   +2 more
openaire   +2 more sources

Eschar Formation from Testosterone Patch

New England Journal of Medicine, 2012
Charisse Orme, Suguru Imaeda
openaire   +1 more source

[Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].

Nederlands tijdschrift voor geneeskunde, 2000
To report the experience with treatment of hypogonadal men with the scrotal application of testosterone patches.Prospective and descriptive.In 12 unselected hypogonadal men (aged 27-58 years; serum concentration of testosterone < 10 nmol/l) who complained of adverse effects of oral androgen treatment, the treatment was changed to scrotal application of
H, Asscheman, L J, Gooren
openaire   +1 more source

Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme

Lancet, The, 2021
Ruth E Langley, Duncan C Gilbert, Sanjeev Madaan   +2 more
exaly  

Transdermal testosterone patch approved

Inpharma Weekly, 1993
openaire   +1 more source